You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • THU0393 Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies

Article metrics

Article menu

Download PDFPDF

Poster Presentations
Spondyloarthritis - treatment
THU0393 Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies
Free

 

Online download statistics by month:

Online download statistics by month: June 2017 to August 2024

AbstractFullPdf
Jun 2017401
Jul 20171606
Aug 20172602
Sep 20174009
Oct 20172405
Nov 20173807
Dec 20174202
Jan 20182002
Feb 20181804
Mar 20183604
Apr 20183604
May 20182800
Jun 20182601
Jul 20183400
Aug 20182002
Sep 20181002
Oct 2018400
Nov 20181603
Dec 20181401
Jan 2019802
Feb 2019804
Mar 20191005
Apr 2019202
May 20193407
Jun 20191407
Jul 2019603
Aug 2019603
Sep 20192004
Oct 2019604
Nov 2019604
Jan 2020802
Feb 2020203
Mar 20201007
Apr 20201003
May 2020403
Jun 2020600
Jul 2020802
Aug 20201002
Sep 20203005
Oct 20201604
Nov 20201603
Dec 20201004
Jan 2021003
Feb 2021401
Mar 2021401
Apr 2021201
May 2021705
Jun 2021004
Jul 2021005
Aug 2021007
Sep 2021005
Oct 20210019
Nov 20214016
Dec 2021605
Jan 2022204
Feb 2022403
Mar 20222003
Apr 2022401
May 2022805
Jun 20221803
Jul 2022800
Aug 2022803
Sep 2022605
Oct 2022803
Nov 202210011
Dec 2022400
Jan 20231003
Feb 2023200
Mar 20231000
Apr 2023200
May 2023002
Jun 2023402
Jul 2023002
Sep 2023001
Nov 2023201
Dec 2023801
Jan 2024201
Feb 2024204
Mar 20243019
Apr 2024404
May 20242401
Jun 20242301
Jul 20242003
Aug 20241401
Total9590297